Solanezumab is a humanized monoclonal antibody designed to increase clearance of soluble amyloid beta (Aβ) from the brain by binding to aggregated forms of Aβ.
News and Features
The FDA panel reviewed data from 5 clinical studies, including the phase 3 AReSVi 006 trial.
High vaccine efficacy seen against RSV A and B subtypes, across age groups among those aged 60 years and older, and for those with coexisting conditions
ACP is an investigational complement C5 inhibitor that is designed to decrease the activation of inflammasomes and the formation of membrane attack complex.
No such association seen for Black older adults followed for 15 years, regardless of sleep duration
Vaccination results in lower RSV-mediated lower respiratory tract disease meeting one of three definitions
COVID-19 tied to approximately doubled in-hospital mortality rates versus bacterial or other viral pneumonias
Authors say providers should routinely ask older adults about cannabis use
But polypill with or without aspirin is associated with reduced functional decline for those aged 65 years or older with cardiovascular risk factors
Following sharp decline during COVID-19, RSV-positive acute respiratory infection reemerged during summer 2021, and is linked to lower QOL
Results showed vaccine efficacy of 83.7% against RSV-LRTD, defined by 2 or more symptoms.
The preliminary safety signal was identified by the CDC’s Vaccine Safety Datalink.
Diane Eastabrook provides a compelling series of articles describing how loneliness and isolation are affecting seniors living at home.
The FDA has approved an expanded indication for the Infinity™ Deep Brain Stimulation (DBS) system (Abbott) to include targeting the internal globus pallidus, which may lead to symptom improvement in patients with Parkinson disease.